Biotech company 10x Genomics (NASDAQ:TXG) will be announcing earnings results tomorrow after the bell. Here’s what investors ...

10x Genomics (TXG) could be a solid addition to your portfolio ... one of the most powerful forces impacting stock prices. A company's changing earnings picture is at the core of the Zacks rating.

Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Short interest in 10x Genomics Inc (NASDAQ:TXG) increased during the last reporting period, rising from 12.06M to 12.86M. This put 17.73% of the company's publicly available shares short.

Shivdeep Dhaliwal Life Science Company 10x Genomics Struggles With Profitability, Analyst Says 2025 Guidance Bakes In NIH Funding Uncertainties 10x Genomics reported a Q4 EPS loss of $(0.40 ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

the company surpassed consensus EPS estimates two times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Should You Invest in 10x Genomics (TXG)? Before you invest ...